This trial has ended
Research Title: An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
Sponsor: Genentech
Principal Investigator: Jay Stallman, M.D.
Description: This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in subjects with primary or recurrent CNV secondary to AMD who have completed the treatment phase of a Genentech sponsored study (FVF2598g, FVF2587g, or FVF2428g) or subjects with macular edema secondary to RVO who have completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g or FVF4166g). The study will enroll two subsets of subjects: ranibizumab experienced and ranibizumab-naive. Subjects should be enrolled within 14 days of completion of the 24-month treatment phase of the previous study.
Start Date: September 2006
Recruitment: Completed
Project Personnel: Leslie Marcus, CCRC
Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084
Clinical Trial Team
Active Trials
Past Trials
- AART C-02-60
- Acucela 4429-202 SEATTLE
- Aerpio AKB-9778-CI-5001 TIME-2b
- Allergan 150998-005 CEDAR
- Allergan 1771-201-008 MAPLE
- Allergan 190342-038 BEACON
- ALLERGAN 206207-012
- AREDS2
- AREDS2 ForeseeHome
- Blair Symington
- C-09-067 RACE
- DRCR.net Protocol N
- Gemini GEM-NH-002 Clarity 2
- Genentech GR39821
- Graybug GBV-102-002 Altissimo
- HORIZON FVF3426g
- KalVista KVD011-201
- LFG316A2203
- MARINA FVF2598g
- Novartis CSPP100A2244
- Ocriplasmin Research to Better Inform Treatment (ORBIT)
- OPH1002
- OPH1004
- Ophthotech OPH2003
- PDEX
- Regeneron R2176-3-AMD-1417 CAPELLA
- Regeneron R910-3-AMD-1517 ONYX
- Regeneron R910-3-DME-1518 RUBY
- Regeneron VGFTe-OD-1411 PANORAMA
- RIDE FVF4168g
- RISE FVF4170g
- Roche BP 30099 BOULEVARD
- Roche BP29647 AVENUE
- Roche GX29176 CHROMA
- Roche GX30191 OMASPECT
- SAILOR FVF3689g
- SCORE
- SCORE2
- Shelby Satterwhite
- Suprachoroidal Buckling for Retinal Detachment
- Taiwan Liposome Company (TLC) TLC399A2002
- Xcenda C-01-17 ForeseeHome